Welcome to our dedicated page for 2Seventy Bio news (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2Seventy Bio stock.
2seventy bio Inc. reports developments centered on Abecma, its FDA-approved CAR T cell therapy for multiple myeloma, and the U.S. collaboration with Bristol Myers Squibb. News commonly covers Abecma commercialization, regulatory and clinical updates, KarMMa study decisions, collaborative arrangement revenue, operating results, cash position, cost management, material agreements, capital-structure disclosures and governance matters.
2seventy bio (Nasdaq: TSVT) reported its Q3 2021 financial results, posting total revenues of $19.3 million, a slight increase from $18.4 million in Q3 2020. The company has accepted its first IND for SC-DARIC33 to treat acute myeloid leukemia, now enrolling patients in a Phase 1 study. Research and development expenses decreased to $61.1 million from $72.3 million year-over-year. Despite a net loss of $60 million, 2seventy remains optimistic about its pipeline and partnerships, particularly with Bristol Myers Squibb for ABECMA, which generated $67 million in revenue.
2seventy bio, Inc. (NASDAQ: TSVT) will participate in a fireside chat at the 5th Annual Cowen IO Next Summit on November 15 at 1:15 PM ET. A webcast will be available for 30 days post-event via their investor relations website. The company is dedicated to developing groundbreaking immuno-oncology therapies, aiming to combat cancer more effectively. Their mission focuses on translating research into actionable therapies, particularly for hematologic malignancies. For more details, visit www.2seventybio.com.
2seventy bio (NASDAQ: TSVT) has announced that it will present data from its pipeline of oncology cell therapies at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021, in Atlanta, Georgia. Highlights include new pre-clinical data on SC-DARIC33, a CD33-targeting CAR T therapy for acute myeloid leukemia, and updated results from the Phase I CRB-402 study of bb21217, a BCMA-directed CAR T therapy for multiple myeloma. Both presentations aim to showcase advancements in treatment options for hematologic malignancies.
2seventy bio officially launches as an independent, publicly traded company on Nasdaq under the symbol TSVT on November 5. The company, a spin-off from bluebird bio, presents a robust pipeline in immuno-oncology cell therapies, including the recently approved ABECMA for multiple myeloma, which garnered $67 million in its first full quarter. The company is backed by approximately $442 million in cash, ensuring operational funding into 2023. With plans for innovative clinical studies in hematologic and solid tumors, 2seventy aims to transform cancer treatment.